For some women using hormone therapy for menopause, getting the next prescription filled has become much more complicated than simply stopping by the pharmacy.
One pharmacy may not have the usual patch.
Another may have a different strength.
A patient may be told to check somewhere else, ask about another manufacturer or contact her doctor about changing the prescription.
And the problem has become significant enough to get the attention of the U.S. Food and Drug Administration.
According to Reuters reporting on the estradiol patch supply problems, the FDA says it is working with all six manufacturers of estradiol transdermal patches in the United States to increase supply as demand for the menopause treatment continues to rise.
But there’s an important distinction.
The FDA has not officially declared the patches to be in shortage.
That can sound contradictory to women who are already having trouble finding them.
Here’s what’s happening—and what women who currently use an estradiol patch should know before their next refill.
What Exactly Is an Estradiol Patch?
Estradiol is a form of estrogen.
During menopause, estrogen levels decline, which can contribute to symptoms such as hot flashes and other problems that can significantly affect daily life.
Hormone therapy can be used to treat certain menopausal symptoms, depending on an individual’s health history and circumstances.
Estradiol can be delivered in several ways.
One is through a transdermal patch worn on the skin.
The patch releases medication through the skin over time rather than requiring the patient to take estrogen by mouth.
For women who have found a patch and dosage that works well for them, suddenly discovering that their pharmacy cannot fill the usual prescription can be especially frustrating.
Demand Has Been Rising
This isn’t simply a case of one pharmacy forgetting to reorder medication.
Demand for estrogen patches has increased substantially.
Reuters reported earlier this year that rising demand had already strained supplies and forced some patients to search among pharmacies for their prescriptions.
The increase comes amid a much larger change in the national conversation surrounding menopause treatment.
For decades, hormone therapy carried prominent warnings about potential health risks.
In late 2025, the FDA announced steps to remove broad boxed warnings from menopausal hormone therapy products after reviewing the scientific evidence and concluding that the existing labeling did not adequately reflect differences among patients, treatments and timing of therapy.
That change received substantial attention.
So did menopause itself.
Conversations that were once relatively private have increasingly moved into doctors’ offices, workplaces, social media and mainstream health reporting.
More women are asking questions about symptoms.
More are discussing treatment options with healthcare professionals.
And demand for some therapies has increased.
Estradiol patches are now feeling some of that pressure.
The FDA Is Working With Six Manufacturers
The FDA told Reuters that it is working with all six U.S. manufacturers of estradiol transdermal patches.
Those manufacturers are:
Amneal
Bayer
Noven
Sandoz
Viatris
Zydus
The objective is straightforward:
Get more patches into the supply chain.
But increasing pharmaceutical production isn’t necessarily as simple as telling a factory to make twice as many next week.
Transdermal patches are more complicated to manufacture than many traditional tablets.
The medication has to be incorporated into a product that consistently adheres to the skin and delivers the appropriate amount of medication over a specified period.
Manufacturers also operate within regulated production systems that cannot always be expanded quickly.
Reuters reported that some manufacturers are already working to increase output, while others have experienced temporary supply constraints.
The FDA is also helping companies address regulatory issues that could slow efforts to expand production.
Then Why Isn’t This an Official Drug Shortage?
This is where the situation becomes confusing.
A woman can walk into several pharmacies and fail to find her medication while the FDA still doesn’t classify the drug as being in an official shortage.
Those statements aren’t necessarily inconsistent.
Availability can vary by manufacturer, dosage, pharmacy, distributor and location.
A particular pharmacy may be unable to obtain one product even while another version remains available elsewhere.
The FDA told Reuters that estradiol patches remain available despite the access problems.
So the current situation is better understood as significant supply pressure and uneven availability, rather than assuming every estradiol patch everywhere in the country is unavailable.
That distinction matters.
Women shouldn’t conclude from headlines about supply problems that their medication is disappearing.
But patients who rely on a particular patch also shouldn’t assume their next refill will automatically be waiting at their usual pharmacy.
Don’t Wait Until Your Last Patch to Request a Refill
For patients who are already experiencing difficulty finding their usual medication, timing becomes important.
Waiting until the final patch is being used leaves very little room to deal with an availability problem.
That doesn’t mean patients should stockpile medication or refill prescriptions earlier than their pharmacy or insurance allows.
But it does mean this may be a good time to understand the refill process before it becomes urgent.
A patient can ask her pharmacy whether the prescribed patch is currently available and whether there have been recurring difficulties obtaining it.
If availability is uncertain, the pharmacist may be able to explain what options exist.
Another Manufacturer May Not Mean Another Medication
One reason this situation can be confusing is that patients often recognize a medication by the box they receive rather than the actual drug inside it.
Estradiol patches are manufactured by several companies.
That means the same active medication may be available from another manufacturer even when the patient’s usual product isn’t.
However, patches can differ.
Dosage schedules, strengths, adhesive systems and other product characteristics may not be identical.
A pharmacist or prescriber can determine whether another available product is an appropriate substitute.
Patients shouldn’t make that decision themselves simply because two boxes both contain estradiol.
Don’t Cut, Combine or Change Patches on Your Own
Supply problems can tempt people to improvise.
If the pharmacy doesn’t have the usual strength, could two smaller patches replace one larger patch?
Could a higher-dose patch be cut?
Could a patch be worn longer?
Could a different estrogen product be substituted?
Those are questions for a pharmacist or healthcare professional.
Medication delivery through a transdermal patch depends on how the particular product is designed.
Changing how a patch is used can alter how the medication is delivered.
The safest approach is simple:
If the prescribed product isn’t available, ask what medically appropriate alternatives exist rather than trying to create one at home.
Your Pharmacist May Be the Fastest Person to Ask First
When medication availability changes, patients sometimes assume the first call has to be to the doctor’s office.
Often, the pharmacy can provide useful information before that call.
A pharmacist may be able to tell you:
Whether your usual patch is temporarily unavailable.
Whether another manufacturer is available.
Whether another nearby location has stock.
Whether a substitution requires a new prescription.
Whether your insurance creates restrictions around an alternative product.
That information can make a conversation with the prescriber much more productive if a prescription change is necessary.
Instead of simply saying, “The pharmacy doesn’t have my patch,” the patient may be able to explain exactly which strengths or manufacturers are available.
Insurance Can Complicate a Simple Switch
Finding another patch doesn’t automatically mean an insurance plan will cover it in exactly the same way.
Formularies can differ.
Copays can differ.
A different product may require additional authorization.
That’s another reason to start asking questions before the medication is nearly gone.
If a pharmacy suggests an alternative, ask whether the insurance plan covers it and whether the prescriber needs to submit anything additional.
A supply problem is frustrating enough without discovering at the register that the available alternative costs significantly more.
Don’t Stop Hormone Therapy Based on a Headline
News about medication availability can easily create anxiety.
But this isn’t a recall.
The FDA hasn’t announced that estradiol patches are unsafe.
And the current access problems don’t mean every woman using a patch needs to change treatment.
This is a supply and availability issue.
Patients shouldn’t stop prescribed hormone therapy or change the dose because they read that patches are difficult to find.
Treatment decisions should be made with the healthcare professional managing the patient’s menopause care.
The Bigger Story Is How Quickly Menopause Care Is Changing
The estradiol patch situation reveals something larger than a pharmaceutical supply problem.
Menopause treatment in the United States is changing rapidly.
For years, many women felt they had relatively little information about what was happening to their bodies or what treatment options existed.
Now the conversation has changed.
Patients are asking more questions.
Doctors are revisiting older assumptions.
The FDA has reconsidered longstanding warnings.
And demand for treatment has risen enough that manufacturers are trying to catch up.
That’s progress in one sense.
Women are seeking care for symptoms they may once have simply endured.
But increased demand also exposes weaknesses in the supply chain.
A treatment isn’t truly accessible simply because it exists.
Patients have to be able to obtain it.
What Women Using Estradiol Patches Can Do Right Now
There is no reason for every woman using an estradiol patch to panic or immediately change anything.
But there is a reason to plan ahead.
If your refill is approaching, check with your pharmacy before you’re down to the final patch.
If your usual product isn’t available, ask whether another manufacturer or strength is available and whether your prescription would need to be changed.
If a change is necessary, involve your pharmacist and prescriber rather than adjusting the medication yourself.
And remember the most important distinction in the current news:
Women are experiencing real difficulty finding certain estradiol patches, and the FDA is actively working with manufacturers to increase supply—but the agency has not declared an official nationwide shortage.
For a woman who has finally found a menopause treatment that works, that distinction may not make an empty pharmacy shelf any less frustrating.
But knowing about the problem before the next refill could give her something valuable:
Time to find another appropriate option before the medication runs out.
Original reporting: Reuters, September 3, 2026. The FDA’s actions regarding menopausal hormone-therapy labeling provide additional background on the changing treatment landscape.